Abbott Laboratories

Shortcut’s reasoning.

The product and geography build estimates revenue of $12,921.35m: Nutrition $2,202.25m, Diagnostics $3,249.18m, Established Pharma $1,610.44m, Medical Devices $5,854.49m and $5m of other revenue. Growth assumptions and estimated comparable bases remain analyst judgments.

The governing consolidated build applies adjusted gross margin of 58.2%, R&D of 6.9% of revenue and SG&A of 27.7%, producing $3,049.44m of adjusted operating earnings. Interest and other items give $2,919.44m of adjusted pre-tax income; a 15.2% tax rate gives $2,475.68m of adjusted net income.

After a 0.4% two-class allocation and 1,734.64m diluted shares, underlying adjusted EPS is 1.4214952238814957. The issuer-style two-decimal forecast is $1.42 versus frozen normalized Street EPS of $1.41. Beat probability is separate and does not multiply EPS.

HIGH unresolved limitation: the consolidated margin build and the segment cost extrapolations remain unreconciled. Alternative cost and margin assumptions give roughly $1.33–$1.41 EPS. These are sensitivities, not corrections or verified issuer guidance; the forecast retains its original assumptions.